ABS and Persona AI Partner to Bring Humanoid Robotics to Shipyards, Advancing Safety and Productivity
24.9.2025 01:01:00 EEST | Business Wire | Press release
A groundbreaking collaboration to develop inspection technologies for Persona AI’s humanoid robot platform that enhances productivity and safety in shipyards was formalized today with the signing of an MOU between ABS and Persona AI.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250923457571/en/
Conceptual image is courtesy of Persona AI
The initiative will focus on adapting Persona AI’s humanoid robots, based in part on NASA’s robotic hand technology, for a range of shipyard tasks. Unlike traditional industrial robots, humanoid robots are uniquely suited to operate in shipyards designed for human workers, offering flexibility and mobility in complex, confined, or ergonomically challenging spaces.
Under the MOU, ABS and Persona AI will collaborate on a series of joint development projects, collecting data to support classification during ship construction.
Ultimately, it will support development of new ABS standards for the types and quality of data required to support digital and remote survey techniques. These standards will not only guide future robot design but also help understand how to collect, evaluate, and apply robotic data for certification and compliance purposes.
“ABS is proud to lead the way in advancing the safe integration of emerging technologies into the maritime industry,” said John McDonald, ABS President and Chief Operating Officer. “This collaboration with Persona AI reflects our commitment to innovation and safety, as we work to establish the standards and protocols that will enable humanoid robots to perform complex tasks reliably and securely in shipyard environments. By combining cutting-edge robotics with ABS’s deep expertise in certification and safety, we’re helping shape a smarter, safer future for shipbuilding.”
This marks a defining moment for the shipbuilding industry,” said Nic Radford, CEO and Co-Founder of Persona AI. “Partnering with ABS, the global authority on maritime standards, demonstrates that humanoid robotics are no longer a distant concept but on a path toward certified reality, set to transform how this industry builds, innovates, and competes.
The project will leverage ABS’ extensive investment in AI evaluation of data and data quality. A copy of Verification and Validation of Models, Simulations, and Digital Twins is available to download here.
ABS is a world leader in supporting the development and application of technology innovation at sea. More information is available here.
About ABS
ABS, a global leader in classification services, is focused on delivering a safer, cleaner future for the marine and offshore industries. For over 160 years, ABS has been setting standards for safety and excellence and continues to innovate in the fields of clean technology, digitalization and artificial intelligence, providing industry-leading technical advisory services. With a global network of surveyors, engineers, technology specialists and support staff, ABS works with industry leaders including its members and clients around the world to improve safety in operational performance and efficiency with innovative solutions for the complete life cycle of marine and offshore assets.
About Persona AI
Persona Al, a pioneering robotics company headquartered in Houston, Texas, is at the forefront of developing intelligent humanoid robots specifically designed for a wide array of industrial applications. Established in 2024, Persona Al leverages a rich heritage of expertise, drawing from decades of experience in crafting sophisticated robotics for demanding environments, including space and deep-ocean exploration. This unparalleled background enables the company to address real-world labor challenges with innovative and robust solutions. Learn more at www.personainc.ai.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250923457571/en/
Contacts
For more information, contact ABS Media Relations: jmire@eagle.org
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom